{"id":19001,"date":"2022-01-17T10:05:45","date_gmt":"2022-01-17T09:05:45","guid":{"rendered":"https:\/\/www.idisantiago.es\/grupo-de-investigacion\/c043-neuroimagen-y-biotecnologia\/"},"modified":"2026-10-14T15:28:14","modified_gmt":"2026-10-14T13:28:14","slug":"c043-neuroimagen-y-biotecnologia","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/en\/grupo-de-investigacion\/c043-neuroimagen-y-biotecnologia\/","title":{"rendered":"C043 – Neuroimaging and Biotechnology"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||||false|false” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” custom_padding=”0px||||false|false” locked=”on” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\u00c1REA: NEUROCIENCIAS<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.idisantiago.es\/wp-content\/uploads\/2021\/11\/grupo_investigacion.jpg” title_text=”Corporate portrait of office workers and employees” disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][\/et_pb_image][et_pb_toggle title=”Objectives and lines of research” disabled_on=”off|off|off” admin_label=”Objetivos y l\u00edneas de investigaci\u00f3n” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Objectives<\/h3>\n

The proposed research group is distinguished by its multidisciplinary origins, bringing together diverse research profiles: its core structure comprises clinical staff alongside researchers specializing in Biology, Veterinary Science, Chemistry, Physics, and Optics and Optometry.<\/p>\n

The group’s objectives focus on:<\/p>\n

– Ischemic stroke and intracerebral hemorrhage: Observational studies and the search for prognostic biomarkers. The goal is to investigate the relationship between clinical improvement in patients with ischemic stroke or intracerebral hemorrhage and blood markers of excitotoxicity and inflammation, as well as other time-dependent clinical and neuroimaging variables.<\/p>\n

– Study of blood-brain barrier (BBB) \u200b\u200bimpairment and small-vessel disease. Endothelial dysfunction is considered fundamental to the pathological processes of small-vessel disease, which may be implicated in the onset and progression of leukoaraiosis (LA). Currently, there are no sensitive or specific biomarkers to accurately assess BBB dysfunction, LA, or stroke. Nor are there MRI imaging probes capable of providing precise information regarding the BBB.<\/p>\n

– Molecular imaging for thrombus characterization in ischemic stroke. While the administration of tissue plasminogen activator (tPA) has improved the prognosis for ischemic stroke patients, its clinical use is limited by a narrow therapeutic window. This is primarily due to the risk of hemorrhagic transformation, which increases over time following symptom onset and depends on the type and size of the thrombus. Specifically, we propose to demonstrate *in vivo* the diagnostic utility of novel dual-function nanoparticles for visualizing and characterizing thrombus structure and size during the acute phase of cerebral ischemia.<\/p>\n

– Novel contrast agents for Magnetic Resonance Imaging (MRI). Development and *in vitro* and *in vivo* testing of new magnetic resonance imaging agents based on Gd, Fe, or \u00b9\u2079F compounds to characterize the damaged region.<\/p>\n

– Nanomedicine applied to glioblastoma treatment. Within this line of work, the group focuses on developing new brain tumor treatments based on both CAR-T cell immunotherapy and nanomedicine using cytotoxic agents.<\/p>\n

– Study of neurological diseases via liquid biopsy. Development of a liquid biopsy for neurological diseases targeting extracellular vesicles (EVs) from cerebral endothelial cells. The main outcome of this project will be a new diagnostic tool to identify patients at risk of developing neurological diseases.<\/p>\n

– Design of lactoferrin-loaded lipid nanoparticles (NPLf) for ocular application, biofunctionalized to target TLR2 using neutralizing monoclonal antibodies. These nanoparticles will incorporate a fluorescent probe for microscopy visualization and a chelating agent for biodistribution studies.<\/p>\n

– Development of an *ex vivo* keratoconus (KC) model. To this end, we will use corneal epithelial tissue from KC patients (obtained from corneal transplants) and healthy corneas (from donors)\u2014sourced from a tissue biobank\u2014to establish organotypic cultures.<\/p>\n

– Ocular TLR2 topography via the study of receptor distribution in the *ex vivo* KC model using NPLf. Confocal microscopy analysis of the distribution pattern (signaling) of targeted nanoparticles across the various layers of KC-affected corneal tissue and healthy donor corneal tissue.<\/p>\n

– Therapeutic application of NPLf in the KC model. Use of lactoferrin-loaded nanoparticles (NPLf) as inflammation modulators and TLR2 blockers, achieved through biofunctionalization with neutralizing anti-TLR2 antibodies.<\/p>\n

– *In vivo* study of NPLf bioavailability in animal models.<\/p>\n

Lines of research<\/h3>\n

\u2022 Ischemic stroke and intracerebral hemorrhage: observational studies and the search for prognostic biomarkers
\u2022 Temperature and brain injury
\u2022 Study of blood-brain barrier disruption and small vessel disease
\u2022 Molecular imaging for thrombus characterization in ischemic stroke
\u2022 Novel MRI contrast agents
\u2022 Development of MRI sequences and post-processing for brain injury assessment; AI in biomedical applications
\u2022 Nanoparticles as vectors for stroke treatment
\u2022 Nanomedicine applied to glioblastoma treatment
\u2022 Study of neurological diseases via liquid biopsy
\u2022 Corneal neurodegenerative diseases
\u2022 Theranostics for keratoconus
\u2022 Inflammation markers in corneal neurodegenerative diseases
\u2022 Innate immunity in corneal ectasias and early diagnostic markers
\u2022 Tear proteomics in patients with keratoconus<\/p>\n

 <\/p>\n

[\/et_pb_toggle][et_pb_toggle title=”Research team” admin_label=”Equipo investigador” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n

Leader<\/strong>
Iglesias Rey, Ram\u00f3n<\/p>\n

Co-leader<\/strong>
Lema Gesto, Isabel<\/p>\n

Members<\/strong>
Abengoza Bello, Mar\u00eda Teresa
Alvite Pi\u00f1eiro, Tania
Amodeo Oblitas, Crhistian Mario
Bazarra Barreiros, Marcos
Cao Cancelas, Alejandro
Fern\u00e1ndez Rodicio, Sabela
Garc\u00eda Acevedo, Pelayo
Garc\u00eda Astray, Luc\u00eda
Gonz\u00e1lez Sim\u00f3n, Inmaculada
Hervella Lorenzo, Pablo
L\u00f3pez L\u00f3pez, Maite
Mari\u00f1o Baca, Alba
Ortega Espina, Sara
Pumar Cebreiro, Jos\u00e9 Manuel
Ramallo Pita, Miriam
Regueiro Lorenzo, Ux\u00eda
Rodr\u00edguez Fern\u00e1ndez, Marta
Sampedro Viana, Ana
Vali\u00f1o Cultelli, Mar\u00eda Victoria<\/p>\n

External Collaborator Staff<\/strong>
Castillo S\u00e1nchez, Jos\u00e9
Guerra Martinuzzi, Alessia<\/p>\n

[\/et_pb_toggle][et_pb_toggle title=”Projects” disabled_on=”off|off|off” admin_label=”Proyectos (cambiar s\u00f3 codigo IDIS)” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ locked=”off” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Ferroptosis y disfunci\u00f3n mitocondrial en queratocono: caracterizaci\u00f3n por microscop\u00eda multifot\u00f3n y abordaje farmacol\u00f3gico<\/strong>
Project code: PI26\/00740
Funding entity: Instiuto de Salud Carlos III
Duration: 2027-2029
Amount: 165.000 \u20ac
Pl: Ux\u00eda Regueiro \/ M\u00aa Isabel Lema<\/p>\n

Consolidaci\u00f3n y estructuraci\u00f3n de Unidades de Investigaci\u00f3n Competitiva<\/strong>
Project code: IN607A2026-06
Funding entity: Axencia Galega de Innovaci\u00f3n
Duration: 2026-2029
Amount: 340.000 \u20ac
PI: Ram\u00f3n Iglesias Rey<\/p>\n

Agentes biomoleculares para diagn\u00f3stico y prevenci\u00f3n de la disfunci\u00f3n de la barrera hematoencef\u00e1lica<\/strong>
Project code: PI24\/00813
Funding entity: Instituto de Salud Carlos III
Duration: 2025-2027
Amount: 177.500 \u20ac
PI: Ram\u00f3n Iglesias Rey<\/p>\n

Tromboimaxe molecular por resonancia magn\u00e9tica con nanopart\u00edculas de fl\u00faor-19 (Tromboimaxe-19F)<\/strong>
Project code: SA304D-PRIS-T-2024\/03
Funding entity: Axencia Galega para o Co\u00f1ecemento en Sa\u00fade
Duration: 2024-2025
Amount: 50.000 \u20ac
PI: Ram\u00f3n Iglesias Rey<\/p>\n

Identification of imaging biomarkers of thrombosis as a support tool for endovascular therapy in ischemic stroke patients. EBRAINS. EBRAINS Open Calls Management.<\/strong>
Project code: EBRAINS 2.0, European Union\u2019s Research and Innovation Program Horizon Europe (No.101147319)
Funding entity: Horizon Europe 2024
Duration: 2024-2026
Cuant\u00eda: 60.000 \u20ac
Investigador\/a principal: Ram\u00f3n Iglesias Rey<\/p>\n

Sensores Proteicos para Imagen de Resonancia Magn\u00e9tica como diagnostico neurol\u00f3gico<\/strong>
Project code: DTS23\/00103
Funding entity: Instituto de Salud Carlos III
Duration: 2024-2025
Amount: 176.000 \u20ac
PI: Pablo Hervella Lorenzo<\/p>\n

Lactoferrina en el queratocono: estudio biomec\u00e1nico y aplicaci\u00f3n terap\u00e9utica nanomolecular.<\/strong>
Project code: PI23\/00323
Funding entity: Instituto de Salud Carlos III
Duration: 2024-2026
Amount: 146.250 \u20ac
PI: M\u00aa Isabel Lema Gesto; Ux\u00eda Regueiro Lorenzo<\/p>\n

LipoCART. Nanoparticulas lipidicas para la activacion de CAR-T en tumores cerebrales<\/strong>
Project code: PID2022-141258OB-I00
Funding entity: Ministerio de Ciencia e Innovaci\u00f3n
Duration: 2023-2026
Amount: 160.625 \u20ac
PI: Pablo Hervella Lorenzo<\/p>\n

EURONANOMED2021-113: LDL-like nanoparticles for CAR-T-based lioblastoma immunotherapy<\/strong>
Project code: AC21_2\/00014
Funding entity: ERA-NET EuroNanoMed III
Duration: 2022-2025
Amount: 1.226.028 \u20ac
PI: Pablo Hervella<\/p>\n

Microscopio Multifoton. Instituto de Salud Carlos III.<\/strong>
Project code: IFCS21\/00014
Funding entity: Instituto de Salud Carlos III
Duration: 2022-2025
Amount: 1.209.335 \u20ac.
PI: Pablo Hervella<\/p>\n

Consolidaci\u00f3n y estructuraci\u00f3n de Unidades de Investigaci\u00f3n Competitiva\u00a0<\/strong>
Project code: IN607A2022-03
Funding entity: Axencia Galega de Innovaci\u00f3n
Duration: 2022-2025
Amount: 320.000 \u20ac
PI: Ram\u00f3n Iglesias Rey<\/p>\n

Nanopart\u00edculas para prevenir el envejecimiento cerebral.<\/strong>
Project code: PI21\/01256
Funding entity: Instituto de Salud Carlos III
Duration: 2022-2025
Amount: 208.120 \u20ac
PI: Ram\u00f3n Iglesias Rey<\/p>\n

[\/et_pb_toggle][et_pb_toggle title=”Publicaciones” disabled_on=”on|on|on” admin_label=”Publicaciones” _builder_version=”4.16″ _module_preset=”default” body_font=”|300|||||||” disabled=”on” global_colors_info=”{}”]<\/p>\n

    \n
  • Publicaci\u00f3n 1<\/li>\n
  • Publicaci\u00f3n 2<\/li>\n
  • Etc.<\/li>\n<\/ul>\n

    [\/et_pb_toggle][et_pb_toggle title=”Web del grupo” disabled_on=”on|on|on” admin_label=”Web del grupo” _builder_version=”4.16″ _module_preset=”default” body_font=”|300|||||||” disabled=”on” global_colors_info=”{}”]<\/p>\n

    https:\/\/<\/p>\n

    [\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Investigador\/a l\u00edder” _builder_version=”4.19.4″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_align=”left” header_2_text_color=”#FFFFFF” background_color=”#10294c” custom_margin=”0px||||false|false” custom_padding=”6px||0px|6px|false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

    Lead researcher<\/h2>\n

    [\/et_pb_text][et_pb_text admin_label=”WP Team (cambiar s\u00f3 a ID pola do l\u00edder de equipo)” _builder_version=”4.16″ _module_preset=”default” locked=”off” global_colors_info=”{}”]<\/p>\n